Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22389065 | 0.78 | L3MBTL1 (0.36) | LMNAPTGS1PTGS2 | |
| SCHEMBL836019 | 0.75 | PTGS1 (0.47) | POLBLMNAPTGS1PTGS2 | |
| SCHEMBL20057574 | 0.74 | MTNR1A (0.41) | NAMPTLMNAPTGS1 | |
| SCHEMBL24611541 | 0.72 | KMT2A (0.32) | — | |
| SCHEMBL12581439 | 0.69 | MGLL (0.54) | LMNAPTGS1PTGS2 | |
| SCHEMBL22422923 | 0.69 | PTGS1 (0.38) | POLBLMNAPTGS1PTGS2 | |
| SCHEMBL19479888 | 0.68 | PTGS1 (0.61) | LMNAHDAC3HDAC1HDAC8PTGS1 | |
| SCHEMBL14395731 | 0.68 | PTGS1 (0.37) | POLBLMNAPTGS1PTGS2 | |
| SCHEMBL12146979 | 0.67 | PTGS1 (0.64) | LMNAHDAC3HDAC1HDAC8PTGS1 | |
| SCHEMBL3646852 | 0.67 | PTGS1 (0.64) | LMNAHDAC3HDAC1HDAC8PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023230-A1 | CONJUGATES OF AN IL-2 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS (US) | 2021-01-28 | — | — | US | disclosed |
| US-10759905-B2 | Biodegradable amphiphilic polymer, polymeric vesicles prepared therefrom, and application of biodegradable amphiphilic polymer in preparation of medicines for targeted therapy of lung cancer | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-20200062897-A1 | Biodegradable Amphiphilic Polymer, Polymer Vesicle Prepared Therefrom and Use in Preparing Target Therapeutic Medicine for Lung Cancer | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062897-A1 | Biodegradable Amphiphilic Polymer, Polymer Vesicle Prepared Therefrom and Use in Preparing Target Therapeutic Medicine for Lung Cancer | PICALM, LETM1, SDCBP | OPRM1 2156/4885NAMPT 4806/4885BAZ2B 3943/4885 |
| US-10759905-B2 | Biodegradable amphiphilic polymer, polymeric vesicles prepared therefrom, and application of biodegradable amphiphilic polymer in preparation of medicines for targeted therapy of lung cancer | PICALM, ACIN1, SGMS2 | OPRM1 1978/4885NAMPT 4758/4885BAZ2B 3988/4885 |
| US-20210023230-A1 | CONJUGATES OF AN IL-2 MOIETY AND A POLYMER | IL2, IL2RA, ILF2 | OPRM1 2942/4885NAMPT 3372/4885BAZ2B 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.